Johnson & Johnson vaccine – developed by subsidiary Janssen – is effective against Covid! This Friday January 29, 2021 the American laboratory announced in a release their product successfully completed all clinical trials, and is 66% effective. It can go up to 85% in preventing severe diseases 28 days after the injection, and 100% 49 days after.
The vaccine is easy to store, safe and effective, and only one dose is needed to prevent the disease. The laboratory is said to now have “a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic”. What is this product about? It is similar to vaccines developed by AstraZeneca and Sputnik V, as it is viral vector vaccine. The principle? A piece of the virus’s RNA is put within inactivated adenovirus and then injected to the patient so that their immune defenses can step in and produce antibodies.
Even though not all data have been released, the vaccine is very promising, searchers also guarantee there is no severe adverse effect: “sometimes pain in the arm, sometimes a little bit of fatigue” Janssen’s global head of research and development Dr. Mathai Mammen explains. The laboratory adds that the vaccine is also working – to a lesser extent – against the South-African variant, it is estimated to be 57% effective – above the 52% required by WHO for issuance.
Johnson & Johnson is then now soon to be seeking approval for marketing authorization to the Food & Drug Administration. In Europe, the European Medicines Agency is also expecting their marketing authorization application, the vaccine being already submitted to “continuous examination” likely to make decisions as for approval easier.
